Service offers convenient monthly runs at $990 per compound to streamline DILI testing in 3D primary human hepatocytes
As part of our growing portfolio of in-house standardized 3D InSight™ testing services, InSphero has launched a 14 Day Hepatotoxicity Testing Service to simplify DILI testing in patent-pending 3D InSight™ Human Liver Microtissues. At just $990 per compound, customers receive repeat-dose 14 day toxicity assessment in primary human hepatocyte/Kupffer cell co-culture microtissues, with results returned three weeks after the initial dosing. IC50 dose-response curves are delivered for the test compound(s) as well as vehicle control and two positive controls (Chlorpromazine and Ketoconazole) using the Promega CellTiter-Glo® Cell Viability Assay (measuring total spheroid ATP content). Monthly runs initiate on the first Tuesday of every month beginning November 3 and December 1, 2015.
How will your compounds perform in 3D?